S1P Receptor Modulators via Phosphate Surrogates and Cyclodextrins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel, potent, and selective agents that can modulate the S1P receptor, specifically the S1P1 receptor, due to the lack of receptor type selective ligands and the complexity of synthesizing sphingosine 1-phosphate analogs with limited solubility, which hinders the development of pharmacological tools for studying physiological processes associated with S1P receptor agonism.
Innovation Solution
Development of sphingosine 1-phosphate analogs with a phosphate moiety and hydrolysis-resistant surrogates like phosphonates and phosphothionates, as well as pro-drugs that are activated by sphingosine kinase, specifically targeting the S1P1 receptor for agonist activity, and providing compounds with specific structural formulas (I and II) and their esters, salts, and stereoisomers for enhanced oral availability and therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sphingosine 1-phosphate analogs are synthesized to achieve potent S1P receptor agonist activity, then receptor modulating efficacy is improved, but solubility is reduced making synthesis and pharmaceutical development difficult
Solution Approach 1:
The patent uses cyclodextrins as intermediary molecules to solubilize the hydrophobic S1P analogs. The cyclodextrin forms inclusion complexes with the analogs, providing aqueous solubility without interfering with the pharmacological activity at the S1P receptor, thus resolving the contradiction between efficacy and solubility
Solution Approach 2:
The patent modifies the chemical structure of S1P analogs by introducing various substituents and side chains (changing molecular parameters) to optimize the balance between receptor binding affinity and solubility properties, allowing potent agonist activity while improving pharmaceutical characteristics
2Object-affected harmful factors
If receptor selective ligands are developed to achieve tissue and response specificity, then side effects are reduced, but synthesis complexity increases due to lack of selective ligands
Solution Approach 1:
The patent introduces specific substituents at particular positions on the S1P analog structure (local structural modifications) to achieve selectivity for specific S1P receptor subtypes. This allows differential binding to various S1P receptors, enabling tissue and response specificity while managing synthesis complexity through systematic structure-activity relationship approaches
3Stability of the object's composition
If phosphate surrogates like phosphonates and phosphothionates are used to create hydrolysis-resistant compounds, then metabolic stability is improved, but structural complexity increases
Solution Approach 1:
The patent systematically replaces the phosphate group in S1P with various surrogate groups (phosphonate, phosphothionate, and other hydrolysis-resistant alternatives), changing the chemical parameters to achieve metabolic stability. This substitution strategy provides structural variants that resist enzymatic degradation while maintaining the essential pharmacophore features for S1P receptor binding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds act as potent and selective agonists for S1P1, S1P4, and S1P5 receptors, offering long-duration action and potential therapeutic benefits in treating autoimmune diseases, chronic pain, progressive dementia, and cancer progression by altering lymphocyte trafficking and inhibiting angiogenesis.
Implementation Method 1
Sphingosine 1-phosphate is formed as a metabolite of sphingosine in its reaction with sphingosine kinase
Implementation Method 2
A conformational shift is induced in the G-Protein Coupled Receptor (GPCR) when the ligand binds to that receptor, causing GDP to be replaced by GTP on the α-subunit of the associated G-proteins
Implementation Method 3
Reversible biodegradation of S1P is believed to proceed via hydrolysis by ectophosphatases such as the S1P phosphohydrolase
Data Source
AI summary
Sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type are provided. The disclosed compounds include an optional phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.